Patents Assigned to Code Biotherapeutics, Inc.
  • Patent number: 12076410
    Abstract: The present disclosure provides nucleic acid carriers comprising one or more layers comprising multiple monomers, wherein each monomer comprises: a first and a second oligonucleotide; wherein a central portion of each of the first and second oligonucleotides is complementary to each other, forming a double-stranded region, wherein the two terminal portions of the first oligonucleotide are not complementary to the two terminal portions of the second oligonucleotide, forming four terminal arms; and at least one targeting agent conjugated to at least one peripheral terminal arm, wherein when the at least one targeting agent is an miRNA. The present disclosure also provides pharmaceutical composition comprising any of the nucleic acid carriers described herein, and a pharmaceutically acceptable vehicle. The present disclosure also provides methods of inducing an immune response in an animal comprising administering to the animal any of the nucleic acid carriers described herein.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 3, 2024
    Assignee: Code Biotherapeutics, Inc.
    Inventors: Robert C. Getts, James M. Kadushin, Lori Getts
  • Patent number: 11802151
    Abstract: The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: October 31, 2023
    Assignee: Code Biotherapeutics, Inc.
    Inventors: Robert Getts, Jessica Bowers, Mindy Ellen George-Weinstein, Jacquelyn Gerhart